Barclays

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Developer of SaaS-based credit card and expense management platform designed to streamline finances and fuel overall growth. The company's platform eliminate the need to supply social security numbers or credit scores and is supported by an integrated software suite that reduces employee time spent on cost management, accounting, and budgeting, enabling entrepreneurs to protect their credit without restricting their capital.